Senior Research Scientist Platform Biology

Arvinas•New Haven, CT

7h•Onsite

About The Position

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit www.arvinas.com and connect on LinkedIn and X. Position Summary We have an exciting opportunity for an experienced scientist to join our biochemical and biophysical assay team in Platform Biology. The selected candidate will participate in assay design, implementation, and data quality control across our programs in ligand discovery and targeted protein degradation. Ideally, the candidate will be experienced in Surface Plasmon Resonance (SPR) and have broad expertise covering various biochemical and biophysical assays and instrumentation. This position will drive assay development, execution and provide the key, critical data necessary to advance programs towards targeted protein degradation in highly disease relevant projects to help human health. This position reports to the Senior Research Investigator, Degrader Mechanisms Group in our Platform Biology department and will be located at our headquarters in New Haven, CT.

Requirements

Skilled, motivated and productive bench scientist with excellent communication and organizational skills who works effectively in a dynamic team setting.
Strong background in protein biochemistry and biophysics; expertise in protein-ligand interactions, induced proximity approaches, or cellular ligand interactions are pluses.
Demonstrated experience in experimental design, execution, and data analysis for protein-protein and protein-ligand interactions using biophysical and/or biochemical techniques; experience with cellular ligand target engagement techniques is a plus.
Demonstrated experience with SPR; additional experience with plate-based assay formats and instrumentation across biochemical and biophysical platforms including TR-FRET, FP, alphaLISA, ASMS, and TSA, are pluses.
Exhibited proficiency in problem solving and analytical thinking skills
Experience outsourcing CRO work and managing projects and timelines.
Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for a current or future VISA sponsorship.
The duties of this role are generally conducted in a lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours.
S. with 7+ years of pharma/biotech or academic experience, or Ph.D with 2+ years of pharma/biotech or academic experience, with a focus on biophysical and/or biochemical assay execution.
Background in protein-protein and protein-ligand interactions and in drug discovery.

Nice To Haves

Background in the protein degradation, induced proximity, and ubiquitin proteasome system are pluses.
Additional training in complimentary biophysical, biochemical, and targeted protein degradation techniques will be provided as needed.

Responsibilities

Biophysical assay design and execution across different modalities, with a focus on SPR and including TSA, DSF, and MST.
Evaluation and implementation of cellular ligand binding and characterization techniques (such as BRET, NanoBRET and other high-throughput cellular target engagement assays)
Biochemical assay design, assay development and execution across different plate-based modalities, such as TR-FRET, FP, and alphaLISA.
Mechanism of action studies of ligand binding and degrader characterization utilizing cellular and biochemical assays.
Manage CRO outsourcing of biochemical and biophysical assays such as ASMS, as necessary.
Data capture, database upload, and presentation of assay development and trouble-shooting data in a clear manner in a group meeting setting.
Partner with diverse project teams in complex scheduling of work and generation of data in support of drug discovery and development programs. Troubleshoot through technical and scientific challenges in order to deliver critical data.
Serve as Platform Lead scientist for assigned projects. Communicate and coordinate Platform activities, and be primary point of contact for biochemical and biophysical needs for assigned projects across wider project teams
Apply excellent organizational and prioritization skills; analyze data using strong background in biochemistry and biophysics and troubleshoot through technical and scientific challenges in order to deliver critical data.
Organize experimental results to be shared with project teams; maintain clear experimental records using ELN (electronic lab notebook).

Benefits

Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more.

Stand Out From the Crowd

Upload your resume and get instant feedback on how well it matches this job.

Upload and Match Resume